Phase II Study Evaluating the Efficacy and Safety of KX-826 in the Treatment of Chinese Male Androgenetic Alopecia

Condition:   Androgenetic Alopecia (AGA) Interventions:   Drug: KX-826-2.5 mg (0.25%)/60 mL BID;   Drug: KX-826-5 mg (5%)/60 mL QD;   Drug: KX-826-5 mg (5%)/60 mL BID;   Other: Placebo Sponsor:   Suzhou Kintor Pharmaceutical Inc, Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials